Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Concentration Versus Time Correlation01:15

Drug Concentration Versus Time Correlation

1.9K
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
1.9K
Time Course of Drug Effect01:14

Time Course of Drug Effect

2.6K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.6K
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

1.7K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.7K
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

231
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
231
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

314
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
314
Drug Concentrations: Measurements01:23

Drug Concentrations: Measurements

1.0K
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomization and allocation procedures for master protocol trials of single-arm studies.

Statistical methods in medical research·2026
Same author

A note on phase I interleaved versus parallel group ascending dose designs for concentration-QTc analyses.

Journal of pharmacokinetics and pharmacodynamics·2025
Same author

Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Using Confidence Distributions in Final and Interim Analyses for Single-Arm Studies or Platform Trials Consisting of Single-Arm Studies.

Statistics in medicine·2025
Same author

Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases.

Neuro-oncology practice·2024
Same author

First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor.

Clinical and translational science·2024

Related Experiment Video

Updated: Jan 14, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.5K

Concentration response analyses for QT data with several active compounds.

Günter Heimann1, Giulia Lestini2, Jochen Zisowsky3

  • 1Advanced Quantitative Sciences / Pharmacometrics, Novartis Pharma AG, Fabrikstrasse 2, Basel, 4002, Switzerland. guenter.heimann@gmx.de.

Journal of Pharmacokinetics and Pharmacodynamics
|January 12, 2026
PubMed
Summary
This summary is machine-generated.

This study introduces a new method for drug development, jointly modeling multiple active compounds to assess their impact on the corrected QT (QTc) interval. The approach provides a formal hypothesis test to exclude a 5 msec QTc effect, improving safety assessments.

Keywords:
Active metabolitesBootstrapCombination drugsConcentration-QTc analyses

More Related Videos

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.7K

Related Experiment Videos

Last Updated: Jan 14, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.5K
High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.7K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Drug Safety and Toxicology
  • Statistical Modeling in Drug Development

Background:

  • Pharmacokinetic-pharmacodynamic (PK-QTc) analyses are standard in drug development, typically assessing single compounds.
  • Multiple active compounds (e.g., parent drugs, metabolites, combination therapies) can complicate PK-QTc assessments.
  • Previous research suggests separate analyses for each compound can yield biased results, advocating for joint modeling.

Purpose of the Study:

  • To propose a formal hypothesis test for excluding a 5 msec corrected QT (QTc) interval effect using joint modeling for two active compounds.
  • To extend existing PK-QTc analysis methods to scenarios involving multiple interacting compounds.
  • To provide a statistically robust method for drug safety evaluation in complex pharmacological profiles.

Main Methods:

  • Developed a joint modeling approach for the impact of two potentially active compounds on the QTc interval.
  • Proposed a formal hypothesis test utilizing upper confidence intervals for key parameters ([Formula: see text], [Formula: see text], [Formula: see text]) to exclude a 5 msec QTc effect.
  • Employed a bootstrap approach for decision-making and validated the method through simulations to control Type I error at 5%.

Main Results:

  • The proposed joint modeling and hypothesis testing approach effectively controls the Type I error rate at 5% in simulations.
  • The method successfully excludes a 5 msec QTc effect when all three upper confidence limits fall below the threshold.
  • The approach is demonstrated for linear exposure-response relationships and adaptable to non-linear scenarios.

Conclusions:

  • Joint modeling provides a more accurate assessment of QTc interval effects when multiple active compounds are present.
  • The proposed hypothesis test offers a reliable method for excluding clinically significant QTc prolongation in drug development.
  • This statistical framework enhances the safety evaluation of drugs with complex pharmacokinetic and pharmacodynamic profiles.